Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) (NCT07044336)
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4 Selected Advanced/Metastatic Endometrial Cancer Who Progressed On or After Platinum Based Chemotherapy and Anti-PD-1/Anti-PD-L1 Therapy (Bluestar-Endometrial01)
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase III, 2-arm, randomized, open label, multicenter, global study assessing the efficacy and safety of puxitatug samrotecan compared to physician's choice of chemotherapy (doxorubicin or paclitaxel) in participants with B7-H4 selected advanced/metastatic EC that progressed following platinum based chemotherapy and anti-PD-1/anti-PD-L1 therapy.
Who can join: Review the eligibility criteria below.
Location: Research Site — Tucson, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (320 Sites)
Showing the first 25 of 320 sites.
- Research Site — Tucson, Arizona
- Research Site — La Jolla, California
- Research Site — Los Angeles, California
- Research Site — Orange, California
- Research Site — Washington D.C., District of Columbia
- Research Site — Jupiter, Florida
- Research Site — Miami, Florida
- Research Site — Miami, Florida
- Research Site — Miami Beach, Florida
- Research Site — New Port Richey, Florida
- Research Site — Orlando, Florida
- Research Site — Tampa, Florida
- Research Site — West Palm Beach, Florida
- Research Site — Honolulu, Hawaii
- Research Site — Chicago, Illinois
- Research Site — Peoria, Illinois
- Research Site — Urbana, Illinois
- Research Site — Fort Wayne, Indiana
- Research Site — Indianapolis, Indiana
- Research Site — Scarborough, Maine
- Research Site — Baltimore, Maryland
- Research Site — Baltimore, Maryland
- Research Site — Silver Spring, Maryland
- Research Site — Ann Arbor, Michigan
- Research Site — Ann Arbor, Michigan
📞 Contact the Study Coordinator
Phone: (877) 240-9479
Email: information.center@astrazeneca.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Endometrial Cancer
- Selective Surgical Staging for the Treatment of Endometrial Cancer Based on Intraoperative Consultation — Lexington, Kentucky
- Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005) — Mobile, Alabama
- Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer — Houston, Texas
- A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer — Little Rock, Arkansas
- Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line — Garran,
- Activity and Cancer Survivorship Exercise Pilot — Iowa City, Iowa
Explore by condition: All Endometrial Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.